LU2458332611
© Globe Newswire
17.12.2025
ALVO
LISTED
ICE
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
News Preview
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDIT...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2025
ALVO
LISTED
ICE
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance
News Preview
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDIT...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ALVO
LISTED
ICE
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
So What: If you purchased Alvotech securities you may be...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
24.11.2025
ALVO
LISTED
ICE
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
News Preview
REYKJAVIK, ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia® and Xgeva® (denosumab)....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
24.11.2025
ALVO
LISTED
ICE
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
News Preview
REYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia® and Xgeva® (denosumab)....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
News Preview
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced tha...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
ALVO
LISTED
ICE
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
News Preview
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech (“Alvotech” or the “Company”) (NASDAQ:ALVO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ALVO
LISTED
ICE
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
News Preview
REYKJAVIK, Iceland, November 12, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and provided a summary of recent pipeline and corporate highlights. Management...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ALVO
LISTED
ICE
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
News Preview
REYKJAVIK, Iceland, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and provided a summary of recent pipeline and corporate highli...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) a...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
06.11.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
News Preview
REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
News Preview
REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, a...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.11.2025
ALVO
LISTED
ICE
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
News Preview
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Applic...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.11.2025
ALVO
LISTED
ICE
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
News Preview
REYKJAVIK, ICELAND (November 2, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
ALVO
LISTED
ICE
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
News Preview
REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to serve as Chief E...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
ALVO
LISTED
ICE
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
News Preview
REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ALVO
LISTED
ICE
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
News Preview
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ALVO
LISTED
ICE
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
News Preview
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending appro...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion rec...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital,...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ALVO
LISTED
ICE
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
News Preview
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ALVO
LISTED
ICE
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
News Preview
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new b...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ALVO
LISTED
ICE
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
News Preview
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-1...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ALVO
LISTED
ICE
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
News Preview
REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ALVO
LISTED
ICE
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
News Preview
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2025
ALVO
LISTED
ICE
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
News Preview
REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highligh...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2025
ALVO
LISTED
ICE
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
News Preview
REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management wil...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2025
ALVO
LISTED
ICE
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
News Preview
Alvotech has appointed Linda Jónsdóttir as its new Chief Financial Officer....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2025
ALVO
LISTED
ICE
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
News Preview
REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
ALVO
LISTED
ICE
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
News Preview
REYKJAVIK, ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (“Ivers-Lee”), a family owned...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
ALVO
LISTED
ICE
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
News Preview
Alvotech acquires capability and added flexibility in assembly and packaging with acquisition of Ivers-Lee Group...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
ALVO
LISTED
ICE
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
News Preview
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights ar...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ALVO
LISTED
ICE
Granting of Stock Options and Vesting of Restricted Share Units
News Preview
In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
News Preview
REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and ra...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
News Preview
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
ALVO
LISTED
ICE
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
News Preview
Lenders have reduced the rate of interest on Alvotech's loan facility reflecting sustained operational improvements and strengthened financial performance...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
ALVO
LISTED
ICE
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
News Preview
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company’s existing senior secured term loan facility, including GoldenTree Asset Management (collec...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ALVO
LISTED
ICE
Main Results of 2025 Annual and Extraordinary General Meeting
News Preview
The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ALVO
LISTED
ICE
Main Results of 2025 Annual and Extraordinary General Meeting
News Preview
REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ALVO
LISTED
ICE
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
News Preview
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, a...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ALVO
LISTED
ICE
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
News Preview
REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Ph...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe,...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
ALVO
LISTED
ICE
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medici...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
ALVO
LISTED
ICE
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
News Preview
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional i...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
ALVO
LISTED
ICE
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
News Preview
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional i...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
ALVO
LISTED
ICE
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
News Preview
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subs...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
ALVO
LISTED
ICE
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
News Preview
HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
ALVO
LISTED
ICE
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
News Preview
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ALVO
LISTED
ICE
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
News Preview
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDI...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ALVO
LISTED
ICE
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
News Preview
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA , AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, W...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ALVO
LISTED
ICE
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
News Preview
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). A...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ALVO
LISTED
ICE
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
News Preview
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Membe...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ALVO
LISTED
ICE
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
News Preview
REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicin...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
News Preview
REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.05.2025
ALVO
LISTED
ICE
Alvotech Annual General Meeting to be held June 25, 2025
News Preview
The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
